Trial · NCT03559192
Results by group68
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 68
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period | Double-blind Treatment + Withdrawal Period: Placebo | -8.0 | Standard Error 0.92 | scores on a scale | |
| Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -10.1 | Standard Error 0.93 | scores on a scale | |
| Change From Treatment Baseline in MADRS Total Score at Treatment Week 6 | Double-blind Treatment + Withdrawal Period: Placebo | -6.5 | Standard Error 0.78 | scores on a scale | |
| Change From Treatment Baseline in MADRS Total Score at Treatment Week 6 | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -9.6 | Standard Error 0.79 | scores on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period | Double-blind Treatment + Withdrawal Period: Placebo | 30 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | 40 | Participants | ||
| Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | -3.7 | Standard Error 0.64 | scores on a scale | |
| Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -4.4 | Standard Error 0.64 | scores on a scale | |
| Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT) | Double-blind Treatment + Withdrawal Period: Placebo | -3.7 | Standard Error 0.55 | scores on a scale | |
| Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -4.5 | Standard Error 0.55 | scores on a scale | |
| Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | -0.76 | Standard Deviation 0.858 | Scores on a scale | |
| Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -0.92 | Standard Deviation 1.039 | Scores on a scale | |
| Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | -0.67 | Standard Deviation 0.880 | Scores on a scale | |
| Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -0.87 | Standard Deviation 1.005 | Scores on a scale | |
| Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | -8.49 | Standard Deviation 9.567 | Scores on a scale | |
| Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -8.03 | Standard Deviation 9.957 | Scores on a scale | |
| Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | -6.91 | Standard Deviation 9.996 | Scores on a scale | |
| Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | -8.16 | Standard Deviation 9.470 | Scores on a scale | |
| Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: Placebo | Overall Depression (Got worse) | 1 | Participants | |
| Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population) | Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) | Overall Depression (Got worse) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03559192/results